Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology ...
Quince Therapeutics will end the development of its lead asset, a treatment for the neurodegenerative disorder ataxia-telangiectasia, after a pivotal Phase 3 trial failed to meet its expected outcomes ...
Johnson & Johnson’s Darzalex Faspro-based quadruplet regimen approved in US for newly diagnosed patients with multiple myeloma who are transplant ineligible: Horsham, Pennsylvan ...
Investing.com -- Quince Therapeutics Inc (NASDAQ:QNCX) stock plunged 13.7% on Thursday after the company announced that its pivotal Phase 3 NEAT clinical trial for Ataxia-Telangiectasia (A-T) failed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results